RATIONALE: Pathological neovascularization is a critical component of diseases such as proliferative retinopathies, cancer and rheumatoid arthritis, yet much remains to be learned about the underlying causes. Previous studies showed that vascular endothelial growth factor (VEGF)-A activates the membrane-anchored metalloproteinase ADAM17 (a disintegrin and metalloproteinase 17) in endothelial cells, thereby stimulating crosstalk between VEGF receptor 2 and extracellular signal-regulated kinase. These findings raised interesting questions about the role of ADAM17 in angiogenesis and neovascularization in vivo. OBJECTIVE: The objective of this study was to inactivate ADAM17 in endothelial cells or in pericytes to determine how this affects developmental angiogenesis, pathological retinal neovascularization and heterotopic tumor growth. METHODS AND RESULTS: We generated animals in which floxed ADAM17 was removed by Tie2-Cre in endothelial cells, or by smooth muscle (sm) Cre in smooth muscle cells and pericytes. There were no evident developmental defects in either conditional knockout strain, but pathological retinal neovascularization and growth of heterotopically injected tumor cells was reduced in Adam17flox/flox/Tie2-Cre mice, although not in Adam17flox/flox/sm-Cre mice. Moreover, lack of ADAM17 in endothelial cells decreased ex vivo chord formation, and this could be largely restored by addition of the ADAM17 substrate HB-EGF (heparin-binding epidermal growth factor-like growth factor). Finally we found that ADAM17 is important for the VEGF receptor 2 stimulated processing of several receptors with known functions in endothelial cell biology. CONCLUSIONS: These results provide the first evidence for a role for ADAM17 in pathological neovascularization in vivo. Because ADAM17 does not appear to be required for normal developmental angiogenesis or vascular homeostasis, it could emerge as a good target for treatment of pathological neovascularization.
RATIONALE: Pathological neovascularization is a critical component of diseases such as proliferative retinopathies, cancer and rheumatoid arthritis, yet much remains to be learned about the underlying causes. Previous studies showed that vascular endothelial growth factor (VEGF)-A activates the membrane-anchored metalloproteinase ADAM17 (a disintegrin and metalloproteinase 17) in endothelial cells, thereby stimulating crosstalk between VEGF receptor 2 and extracellular signal-regulated kinase. These findings raised interesting questions about the role of ADAM17 in angiogenesis and neovascularization in vivo. OBJECTIVE: The objective of this study was to inactivate ADAM17 in endothelial cells or in pericytes to determine how this affects developmental angiogenesis, pathological retinal neovascularization and heterotopic tumor growth. METHODS AND RESULTS: We generated animals in which floxed ADAM17 was removed by Tie2-Cre in endothelial cells, or by smooth muscle (sm) Cre in smooth muscle cells and pericytes. There were no evident developmental defects in either conditional knockout strain, but pathological retinal neovascularization and growth of heterotopically injected tumor cells was reduced in Adam17flox/flox/Tie2-Cre mice, although not in Adam17flox/flox/sm-Cre mice. Moreover, lack of ADAM17 in endothelial cells decreased ex vivo chord formation, and this could be largely restored by addition of the ADAM17 substrate HB-EGF (heparin-binding epidermal growth factor-like growth factor). Finally we found that ADAM17 is important for the VEGF receptor 2 stimulated processing of several receptors with known functions in endothelial cell biology. CONCLUSIONS: These results provide the first evidence for a role for ADAM17 in pathological neovascularization in vivo. Because ADAM17 does not appear to be required for normal developmental angiogenesis or vascular homeostasis, it could emerge as a good target for treatment of pathological neovascularization.
Authors: M L Moss; S L Jin; M E Milla; D M Bickett; W Burkhart; H L Carter; W J Chen; W C Clay; J R Didsbury; D Hassler; C R Hoffman; T A Kost; M H Lambert; M A Leesnitzer; P McCauley; G McGeehan; J Mitchell; M Moyer; G Pahel; W Rocque; L K Overton; F Schoenen; T Seaton; J L Su; J D Becherer Journal: Nature Date: 1997-02-20 Impact factor: 49.962
Authors: Margrit Hollborn; Ianors Iandiev; Marlen Seifert; Ute E K Schnurrbusch; Sebastian Wolf; Peter Wiedemann; Andreas Bringmann; Leon Kohen Journal: Curr Eye Res Date: 2006-10 Impact factor: 2.424
Authors: Bin-Bing S Zhou; Michael Peyton; Biao He; Changnian Liu; Luc Girard; Eian Caudler; Yvonne Lo; Frederic Baribaud; Iwao Mikami; Noemi Reguart; Gengjie Yang; Yanlong Li; Wenqing Yao; Kris Vaddi; Adi F Gazdar; Steven M Friedman; David M Jablons; Robert C Newton; Jordan S Fridman; John D Minna; Peggy A Scherle Journal: Cancer Cell Date: 2006-07 Impact factor: 31.743
Authors: Philip A Clarke; Jacqueline H Dickson; Joseph C Harris; Anna Grabowska; Susan A Watson Journal: Cancer Res Date: 2006-04-01 Impact factor: 12.701
Authors: J J Peschon; J L Slack; P Reddy; K L Stocking; S W Sunnarborg; D C Lee; W E Russell; B J Castner; R S Johnson; J N Fitzner; R W Boyce; N Nelson; C J Kozlosky; M F Wolfson; C T Rauch; D P Cerretti; R J Paxton; C J March; R A Black Journal: Science Date: 1998-11-13 Impact factor: 47.728
Authors: Rolake O Alabi; Krzysztof Glomski; Coline Haxaire; Gisela Weskamp; Sébastien Monette; Carl P Blobel Journal: Circ Res Date: 2016-06-27 Impact factor: 17.367
Authors: Krzysztof Glomski; Sébastien Monette; Katia Manova; Bart De Strooper; Paul Saftig; Carl P Blobel Journal: Blood Date: 2011-06-07 Impact factor: 22.113
Authors: S Leah Etheridge; Michelle E Roh; Megan E Cosgrove; Veena Sangkhae; Norma E Fox; Junmei Chen; José A López; Kenneth Kaushansky; Ian S Hitchcock Journal: Proc Natl Acad Sci U S A Date: 2014-01-27 Impact factor: 11.205